Abstract
Whole-body imaging with Positron Emission Tomography (PET) using F-18 Fluorodeoxyglucose (18F-FDG) has been widely used along with the evaluation and clinical management of neoplasms. The main advantage of using whole-body imaging with 18F-FDG PET in oncology is the ability to detect unexpected or incidental tumor sites. The purpose of this study was to determine the incidentaloma of the 18F-FDG PET examination in nuclear medicine. This research uses the literature study method or literature review. The conclusion of this study is that PET/CT imaging can detect incidental primary tumors and pre-malignant lesions. FDG avidity and lesion morphology assessed by PET and CT images complement each other and help locate these lesions.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
